[Federal Register Volume 88, Number 188 (Friday, September 29, 2023)]
[Notices]
[Page 67360]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-21400]



[[Page 67360]]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1270]


Bulk Manufacturer of Controlled Substances Application: Eli-
Elsohly Laboratories

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Eli-Elsohly Laboratories has applied to be registered as a 
bulk manufacturer of basic class(es) of controlled substance(s). Refer 
to SUPPLEMENTARY INFORMATION listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may submit electronic comments on or 
objections to the issuance of the proposed registration on or before 
November 28, 2023. Such persons may also file a written request for a 
hearing on the application on or before November 28, 2023.

ADDRESSES: The Drug Enforcement Administration requires that all 
comments be submitted electronically through the Federal eRulemaking 
Portal, which provides the ability to type short comments directly into 
the comment field on the web page or attach a file for lengthier 
comments. Please go to https://www.regulations.gov and follow the 
online instructions at that site for submitting comments. Upon 
submission of your comment, you will receive a Comment Tracking Number. 
Please be aware that submitted comments are not instantaneously 
available for public view on https://www.regulations.gov. If you have 
received a Comment Tracking Number, your comment has been successfully 
submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on August 24, 2023, Eli-Elsohly Laboratories, 5 
Industrial Park Drive, Oxford, Mississippi 38655-5343, applied to be 
registered as a bulk manufacturer of the following basic class(es) of 
controlled substance(s):

----------------------------------------------------------------------------------------------------------------
                   Controlled substance                        Drug code                  Schedule
----------------------------------------------------------------------------------------------------------------
Marihuana Extract.........................................            7350  I
Marihuana.................................................            7360  I
Tetrahydrocannabinols.....................................            7370  I
Amphetamine...............................................            1100  II
Methamphetamine...........................................            1105  II
Cocaine...................................................            9041  II
Ecgonine..................................................            9180  II
Codeine...................................................            9050  II
Dihydrocodeine............................................            9120  II
Oxycodone.................................................            9143  II
Dihydromorphine...........................................            9145  II
Thebaine..................................................            9333  II
----------------------------------------------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
for product development and reference standards. In reference to drug 
codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), the company 
plans to isolate these controlled substances from procured 7350 
(Marihuana Extract). In reference to drug code 7360, no cultivation 
activities are authorized for this registration. In reference to drug 
code 9333 (Thebaine), the company plans to manufacture a Thebaine 
derivative. No other activities for these drug codes are authorized for 
this registration.

Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023-21400 Filed 9-28-23; 8:45 am]
BILLING CODE P